US 11,931,227 B2
Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding
Vihar C. Surti, Winston-Salem, NC (US); Shaun D. Gittard, Winston-Salem, NC (US); John C. Sigmon, Jr., Winston-Salem, NC (US); and Gregory Hardy, Winston-Salem, NC (US)
Assigned to COOK MEDICAL TECHNOLOGIES LLC, Bloomington, IN (US)
Filed by Cook Medical Technologies LLC, Bloomington, IN (US)
Filed on Apr. 28, 2017, as Appl. No. 15/581,876.
Application 15/581,876 is a continuation in part of application No. 14/209,718, filed on Mar. 13, 2014, abandoned.
Application 14/209,718 is a continuation in part of application No. 14/044,040, filed on Oct. 2, 2013, granted, now 9,867,931.
Claims priority of provisional application 61/793,586, filed on Mar. 15, 2013.
Prior Publication US 2017/0232141 A1, Aug. 17, 2017
Int. Cl. A61F 13/04 (2006.01); A61F 13/00 (2006.01); A61F 13/02 (2006.01); A61L 15/22 (2006.01); A61L 15/58 (2006.01); A61L 24/00 (2006.01); A61L 26/00 (2006.01)
CPC A61F 13/04 (2013.01) [A61F 13/00063 (2013.01); A61F 13/023 (2013.01); A61F 13/0253 (2013.01); A61L 15/225 (2013.01); A61L 15/58 (2013.01); A61L 24/001 (2013.01); A61L 26/0061 (2013.01); A61L 2300/418 (2013.01); A61L 2400/04 (2013.01); A61L 2400/06 (2013.01)] 15 Claims
 
1. A system for achieving hemostasis of an actively bleeding lesion and maintaining hemostasis of said lesion, comprising:
(i) at least one pressure source;
(ii) at least one catheter;
(iii) a hemostatic powder in a container, the container adapted to be in fluid communication with the at least one pressure source and the at least one catheter; and
(iv) an adhesive powder;
wherein the at least one pressure source is capable of propelling the hemostatic powder first to flow through the catheter to and about the site of the actively bleeding lesion, wherein upon delivery of the hemostatic powder to and about the site of the lesion, a hemostatic layer is formed at and about the site of the lesion, at least partially or completely covering the lesion;
wherein the catheter of the system comprises a multi-lumen catheter, where the hemostatic powder and the adhesive powder are delivered through the multi-lumen catheter;
wherein the system is configured to withhold the adhesive powder from initial delivery to the lesion until the active bleeding has been stopped or slowed by the hemostatic powder, and after the active bleeding has been stopped or slowed by the hemostatic powder, the adhesive powder is capable of being separately delivered to flow on top, over and/or about at least a portion of the hemostatic layer, wherein upon delivery of the adhesive powder, a protective covering is formed at least partially or completely covering the hemostatic layer and surrounding tissue; and
wherein, the hemostatic layer and the protective covering are capable of remaining at and about a site of the lesion for a minimum of 30 minutes.